优化肝素在高危出血神经危重症患者抗凝治疗中的剂量:一项质量改进倡议报告。

IF 1.1 Q4 PHARMACOLOGY & PHARMACY
Sahil Kapoor, Nick Scaturo, Garrett Thompson, Benji Small, Christopher R Newey, Shayn Martin, Peter Miller, Aarti Sarwal
{"title":"优化肝素在高危出血神经危重症患者抗凝治疗中的剂量:一项质量改进倡议报告。","authors":"Sahil Kapoor, Nick Scaturo, Garrett Thompson, Benji Small, Christopher R Newey, Shayn Martin, Peter Miller, Aarti Sarwal","doi":"10.1177/87551225251343558","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Heparin infusions are used to treat and prevent thromboembolic complications in neurocritical care, but optimal dosing in patients with acute intracranial pathology or recent neurosurgery is uncertain, due to elevated risk of hemorrhage. Many institutions customize heparin nomograms for such patients but fail to methodically evaluate their effectiveness. <b>Context</b>: Neurocritical care unit in an academic medical center in the United States. <b>Problem:</b> Several incidents of heparin infusions failing to reach their partial thromboplastin time (PTT) goal within 24 hours of initiation occurred. This created a concern that existing heparin dosing protocol should be adjusted to attain goal PTT more rapidly to better treat thrombotic events. <b>Objective:</b> To reduce time to therapeutic effectiveness of weight-based heparin in neurocritical care patients at high risk of bleeding. <b>Study Design:</b> Quality improvement initiative, comparing data from a retrospective chart review (historical comparison cohort) and a prospective observational quality improvement initiative (QI cohort). <b>Patients:</b> Adult patients with acute intracranial pathology and acute indications for therapeutic anticoagulation but considered at high risk of intracranial hemorrhage. <b>Interventions:</b> Increase heparin dosing nomogram from 12 units/kg/h (historical cohort) to 18 units/kg/h (quality improvement cohort), without an initial bolus in either. <b>Measurements:</b> Primary endpoint was time to therapeutic activated partial thromboplastin time (aPTT) in hours, assessed with a Kaplan-Meier curve. Any known bleeding or thrombotic complications were recorded. <b>Results</b>: Time to reach therapeutic target aPTT was shorter in quality improvement cohort than in historical cohort (see Figure 1 in full text for details). Bleeding complications occurred in 3 of 21 patients in each cohort. <b>Conclusions:</b> Quality improvement initiatives such as this can make documented improvements in health care provided to neurocritical care patients.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251343558"},"PeriodicalIF":1.1000,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103460/pdf/","citationCount":"0","resultStr":"{\"title\":\"Optimizing the Dosing of Heparin for Therapeutic Anticoagulation in Neurocritical Care Patients at High Risk of Bleeding: Report on a Quality Improvement Initiative.\",\"authors\":\"Sahil Kapoor, Nick Scaturo, Garrett Thompson, Benji Small, Christopher R Newey, Shayn Martin, Peter Miller, Aarti Sarwal\",\"doi\":\"10.1177/87551225251343558\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Heparin infusions are used to treat and prevent thromboembolic complications in neurocritical care, but optimal dosing in patients with acute intracranial pathology or recent neurosurgery is uncertain, due to elevated risk of hemorrhage. Many institutions customize heparin nomograms for such patients but fail to methodically evaluate their effectiveness. <b>Context</b>: Neurocritical care unit in an academic medical center in the United States. <b>Problem:</b> Several incidents of heparin infusions failing to reach their partial thromboplastin time (PTT) goal within 24 hours of initiation occurred. This created a concern that existing heparin dosing protocol should be adjusted to attain goal PTT more rapidly to better treat thrombotic events. <b>Objective:</b> To reduce time to therapeutic effectiveness of weight-based heparin in neurocritical care patients at high risk of bleeding. <b>Study Design:</b> Quality improvement initiative, comparing data from a retrospective chart review (historical comparison cohort) and a prospective observational quality improvement initiative (QI cohort). <b>Patients:</b> Adult patients with acute intracranial pathology and acute indications for therapeutic anticoagulation but considered at high risk of intracranial hemorrhage. <b>Interventions:</b> Increase heparin dosing nomogram from 12 units/kg/h (historical cohort) to 18 units/kg/h (quality improvement cohort), without an initial bolus in either. <b>Measurements:</b> Primary endpoint was time to therapeutic activated partial thromboplastin time (aPTT) in hours, assessed with a Kaplan-Meier curve. Any known bleeding or thrombotic complications were recorded. <b>Results</b>: Time to reach therapeutic target aPTT was shorter in quality improvement cohort than in historical cohort (see Figure 1 in full text for details). Bleeding complications occurred in 3 of 21 patients in each cohort. <b>Conclusions:</b> Quality improvement initiatives such as this can make documented improvements in health care provided to neurocritical care patients.</p>\",\"PeriodicalId\":16796,\"journal\":{\"name\":\"Journal of Pharmacy Technology\",\"volume\":\" \",\"pages\":\"87551225251343558\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-05-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103460/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmacy Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/87551225251343558\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/87551225251343558","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:肝素输注用于治疗和预防神经危重症患者的血栓栓塞并发症,但由于出血风险增加,急性颅内病理或近期神经手术患者的最佳剂量尚不确定。许多机构为这类患者定制肝素图,但未能系统地评估其有效性。背景:美国某学术医疗中心的神经危重症监护病房。问题:几个事件的肝素输注未能达到其部分凝血活酶时间(PTT)目标24小时内开始发生。这引起了人们的关注,即现有的肝素剂量方案应该进行调整,以更快地达到PTT目标,更好地治疗血栓性事件。目的:探讨体重型肝素治疗神经危重症高危出血患者的疗效。研究设计:质量改善计划,比较回顾性图表回顾(历史比较队列)和前瞻性观察性质量改善计划(QI队列)的数据。患者:有急性颅内病理和治疗性抗凝的急性指征,但被认为有颅内出血高风险的成年患者。干预措施:将肝素给药图从12单位/kg/h(历史队列)增加到18单位/kg/h(质量改善队列),两组均不开始服用。测量:主要终点是治疗激活部分凝血活素时间(aPTT),以小时为单位,用Kaplan-Meier曲线进行评估。记录任何已知的出血或血栓并发症。结果:质量改善组aPTT达到治疗目标的时间比历史组短(详见全文图1)。每组21例患者中有3例出现出血并发症。结论:诸如此类的质量改进举措可以使提供给神经危重症患者的医疗保健得到有据可查的改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Optimizing the Dosing of Heparin for Therapeutic Anticoagulation in Neurocritical Care Patients at High Risk of Bleeding: Report on a Quality Improvement Initiative.

Background: Heparin infusions are used to treat and prevent thromboembolic complications in neurocritical care, but optimal dosing in patients with acute intracranial pathology or recent neurosurgery is uncertain, due to elevated risk of hemorrhage. Many institutions customize heparin nomograms for such patients but fail to methodically evaluate their effectiveness. Context: Neurocritical care unit in an academic medical center in the United States. Problem: Several incidents of heparin infusions failing to reach their partial thromboplastin time (PTT) goal within 24 hours of initiation occurred. This created a concern that existing heparin dosing protocol should be adjusted to attain goal PTT more rapidly to better treat thrombotic events. Objective: To reduce time to therapeutic effectiveness of weight-based heparin in neurocritical care patients at high risk of bleeding. Study Design: Quality improvement initiative, comparing data from a retrospective chart review (historical comparison cohort) and a prospective observational quality improvement initiative (QI cohort). Patients: Adult patients with acute intracranial pathology and acute indications for therapeutic anticoagulation but considered at high risk of intracranial hemorrhage. Interventions: Increase heparin dosing nomogram from 12 units/kg/h (historical cohort) to 18 units/kg/h (quality improvement cohort), without an initial bolus in either. Measurements: Primary endpoint was time to therapeutic activated partial thromboplastin time (aPTT) in hours, assessed with a Kaplan-Meier curve. Any known bleeding or thrombotic complications were recorded. Results: Time to reach therapeutic target aPTT was shorter in quality improvement cohort than in historical cohort (see Figure 1 in full text for details). Bleeding complications occurred in 3 of 21 patients in each cohort. Conclusions: Quality improvement initiatives such as this can make documented improvements in health care provided to neurocritical care patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Pharmacy Technology
Journal of Pharmacy Technology PHARMACOLOGY & PHARMACY-
CiteScore
1.50
自引率
0.00%
发文量
49
期刊介绍: For both pharmacists and technicians, jPT provides valuable information for those interested in the entire body of pharmacy practice. jPT covers new drugs, products, and equipment; therapeutic trends; organizational, legal, and educational activities; drug distribution and administration; and includes continuing education articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信